QUANTITATIVE METHODS FOR EVALUATING THE PROCESS ACTIVITY IN THE DIAGNOSIS AND TREATMENT OF T-CELLULAR SKIN LYMPHOMAS


如何引用文章

全文:

详细

Precise standardized measurements are essentialfor the diagnosis and treatment of Sezary ’s syndrome (mycosis fungoides). The T-cellular skin lymphoma (T-CSL) severity index (SI) has been suggested in 2005. Evaluation of this index is a simple to use quantitative indicator of the disease activity in cases with involvement of many organs and systems (skin, lymph nodes, circulatory system, viscera) and a prognostically significant characteristic in multifactorial analysis. The index, quantitatively reflecting the disease activity in all involved organs and systems, effectively supplements the TNM classification in clinical practice and research.

作者简介

V. Moiochkov

ГУ МОНИКИ им. М.Ф. Владимирского

д-р мед. наук, проф.

A. Kovrigina

ФГБУ Гематологический научный центр Минздрава России

д-р биол. наук

A. Moiochkov

ГУ МОНИКИ им. М.Ф. Владимирского

д-р мед. наук, проф.

A. Karaulov

Первый МГМУ им. И.М. Сеченова Минздрава России

член-корр. РАМН, д-р мед. наук, проф.

G. Menshchikova

ГУ МОНИКИ им. М.Ф. Владимирского

канд. мед. наук, ассистент

A. Fedorovskaya

ГУ МОНИКИ им. М.Ф. Владимирского

Email: fedorovskaya84@yandex.ru
аспирант

I. Yefimovich

Первый МГМУ им. И.М. Сеченова Минздрава России

Email: iraefimov_115@rambler.ru
аспирант

参考

  1. Criscione V.D., Weinstock M.A. Incidence of cutaneous T-cell lymphoma in the United States, 1973—2002. Arch Dermatol. 2007; 143(7): 854—9.
  2. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105(10): 3768—85.
  3. Bunn P.A.Jr., Lamberg S.I. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep. 1979; 63(4): 725—8.
  4. Kim E.J., Hess S., Richardson S.K., Newton S., Showe L.C., Benoit B.M., et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 2005; 115(4): 798—812.
  5. Kim Y., Reddy S., Kim E.J. et al. Romidepsin (depsipeptide, FK228) induces clinically significant responses in treatment-refractory CTCL: further report of an international, multicenter study. Oral presentation at: American Society of Hematology Meeting, Atlanta, Dec 8—11, 2007. ISSN: 0190-9622. doi: 10.1016/j.jaad.2007.01.044.
  6. Dippel E., Goerdt S., Assaf C., Stein H., Orfanos C.E., et al. Cutaneous T-cell lymphoma severity index and T-cell gene rearrangement. Lancet 1997; 350(9093): 1776—7.
  7. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al.; ISCL/EOrTc. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110(6): 1713—22.
  8. Stevens S.R., Ke M.S., Parry E.J., Mark J., Cooper K.D. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch. Dermatol. 2002; 138(1): 42—8.
  9. The National Comprehensive Cancer Network mycosis fungoides/Sezary syndrome clinical practice guidelines in oncology (version 3.2008) Available from: URL. Accessed December 4, 2008. http://www.nccn.org.

版权所有 © Eco-Vector, 2012


 


##common.cookie##